Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma (Q39930099)

15 September 2017

title

Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma (English)

1 reference

15 September 2017

main subject

multiple drug resistance

1 reference

1 reference

K Noborio-Hatano

1 reference

15 September 2017

J Kikuchi

1 reference

15 September 2017

M Takatoku

1 reference

15 September 2017

R Shimizu

1 reference

15 September 2017

T Wada

1 reference

15 September 2017

M Ueda

1 reference

15 September 2017

M Nobuyoshi

1 reference

15 September 2017

I Oh

1 reference

15 September 2017

K Sato

1 reference

15 September 2017

T Suzuki

1 reference

15 September 2017

K Ozaki

1 reference

15 September 2017

M Mori

1 reference

15 September 2017

T Nagai

1 reference

15 September 2017

K Muroi

1 reference

15 September 2017

Y Kano

1 reference

15 September 2017

Y Furukawa

1 reference

15 September 2017

K Ozawa

1 reference

15 September 2017

language of work or name

English

0 references

publication date

13 October 2008

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

231-242

1 reference

Expression of adhesion molecules on myeloma cells

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

The role of adhesion molecules in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Incorporating bortezomib into the treatment of lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

NF-kB in development and progression of human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Persistent use of false myeloma cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Transfection of antisense core 2 beta1,6-N-acetylglucosaminyltransferase-1 cDNA suppresses selectin ligand expression and tissue infiltration of B-cell precursor leukemia cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the alpha4integrin gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Review of 1027 patients with newly diagnosed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

A new mathematical model for relative quantification in real-time RT-PCR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

A phase 2 study of bortezomib in relapsed, refractory myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.385

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.385

1 reference

Dimensions Publication ID

15 September 2017

1029068965

0 references

1 reference